Approximately 64 million Americans have elevated Lp(a) levels, a particle linked to increased heart attack and stroke risks. Until now, treatments were scarce. However, Eli Lilly has introduced lepodisiran, which can drastically lower Lp(a) levels by 94% with a single injection, lasting six months. Despite this promising development, it's uncertain whether reducing Lp(a) will directly reduce cardiovascular risks, pending more extensive clinical trials. The issue underscores the urgency for increased awareness and testing, as the condition often goes unnoticed by both patients and healthcare providers.
As many as one in five people in the U.S. have elevated levels of Lp(a), increasing the risk of heart attacks and strokes. Few doctors test for it.
Eli Lilly's new drug, lepodisiran, can lower Lp(a) levels by 94% after a single injection, lasting six months without significant side effects.
Dr. David Maron expressed that the reduction in lipoprotein levels with lepodisiran is thrilling, highlighting the potential of this breakthrough treatment.
While the drug shows promise, clinical trials are still necessary to confirm if lowering Lp(a) levels effectively reduces cardiovascular risks.
Collection
[
|
...
]